Episomal Plasmid Vectors with Candida boidinii ARS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing episomal plasmid vectors in Pichia pastoris exhibit low stability and transformation efficiency, limiting their use in heterologous protein expression and protein engineering due to inefficient homologous recombination and high clonal variation, and require methanol induction, which is toxic and undesirable in large-scale bioreactors.
Innovation Solution
Development of episomal plasmid vectors incorporating autonomously replicating sequences (ARS) from Candida boidinii, which are not operably linked to the gene of interest, providing increased transformation efficiency and stability, allowing for high protein yields and uniform expression without the need for methanol induction, and enabling flexible library generation and screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If episomal plasmid vectors are used in Pichia pastoris for heterologous protein expression, then transformation efficiency and stability are improved, but existing vectors exhibit low stability and low expression rates
Solution Approach 1:
The patent changes the ARS sequence parameter by replacing the native Pichia pastoris ARS1 sequence with a heterologous Candida boidinii ARS sequence. This parameter change results in plasmids that are more stable and maintain higher expression rates, resolving the contradiction between plasmid stability and productivity. The heterologous ARS sequence creates a more favorable replication environment that prevents plasmid loss while sustaining high gene expression.
Solution Approach 2:
The patent creates a composite plasmid structure by combining elements from different sources: the Candida boidinii ARS sequence, the Pichia pastoris PCAT1 promoter, and the gene of interest. This composite design leverages the stabilizing effect of the heterologous ARS while maintaining the strong constitutive expression capability of the PCAT1 promoter, achieving both high stability and high expression rates simultaneously.
2Object-affected harmful factors
If the PCAT1 promoter is used for constitutive expression, then methanol-free production is achieved, but expression levels are only 30-40% of methanol-induced PAOX1 in small scale cultivations
Solution Approach 1:
The patent changes the ARS sequence parameter from the native ARS1 to the heterologous C. boidinii ARS sequence, which unexpectedly results in significantly enhanced protein yields when used with the PCAT1 promoter. This parameter change in the replication origin creates a synergistic effect that amplifies the expression output of the PCAT1 promoter, achieving high yields without methanol induction. The improved plasmid stability from the heterologous ARS ensures consistent high-level expression over many generations.
3Adaptability or versatility
If episomal plasmids are used instead of genomic integration, then flexible library generation and screening are enabled, but transformation efficiency and stability are reduced
Solution Approach 1:
The patent changes the ARS sequence parameter to the heterologous C. boidinii ARS, which dramatically improves plasmid stability and transformation efficiency. This parameter change enables episomal plasmids to maintain themselves reliably in P. pastoris cells over many generations, making them suitable for flexible library generation and screening applications. The improved stability allows transformants to maintain the plasmid without selection pressure, enabling easy library manipulation and screening.
4Productivity
If small plasmid size is used to facilitate cloning and obtain high transformation rates, then transformation efficiency is improved, but expression rates and stability may be compromised
Solution Approach 1:
The patent changes the ARS sequence parameter to the heterologous C. boidinii ARS, which provides exceptional plasmid stability and transformation efficiency even in compact plasmid designs. This parameter change allows the plasmid to maintain itself reliably at small sizes, eliminating the trade-off between transformation rate and stability. The heterologous ARS sequence is highly efficient at initiating replication, ensuring that even small plasmids are maintained at high copy numbers with high stability.
Data Source
AI summary
An episomal plasmid comprising a gene of interest (GOI) and an autonomously replicating sequence (ARS) which is not operably linked to the GOI, which ARS comprises or consists of a nucleotide sequence identified as any of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:6-11, or a functionally active variant of any of the foregoing which is characterized by at least 60% sequence identity thereto.